Advanced

Self-sampling with HPV mRNA analyses from vagina and urine compared with cervical samples

Asciutto, Katrin Christine LU ; Ernstson, Avalon LU ; Forslund, Ola LU and Borgfeldt, Christer LU (2018) In Journal of Clinical Virology 101. p.69-73
Abstract

Background: In order to increase coverage in the organized cervical screening program, self-sampling with HPV analyses has been suggested. Objectives: The aim was to compare human papillomavirus (HPV) mRNA detection in vaginal and urine self-collected samples with clinician-taken cervical samples and the corresponding clinician-taken histological specimens. Study design: Self-collected vaginal, urine and clinician-taken cervical samples were analyzed from 209 women with the Aptima mRNA assay (Hologic Inc, MA, USA). Cervical cytology, colposcopy, biopsy and/or the loop electrosurgical excision procedure (LEEP) were performed in every examination. Results: The sensitivity of the HPV mRNA test in detecting high-grade squamous... (More)

Background: In order to increase coverage in the organized cervical screening program, self-sampling with HPV analyses has been suggested. Objectives: The aim was to compare human papillomavirus (HPV) mRNA detection in vaginal and urine self-collected samples with clinician-taken cervical samples and the corresponding clinician-taken histological specimens. Study design: Self-collected vaginal, urine and clinician-taken cervical samples were analyzed from 209 women with the Aptima mRNA assay (Hologic Inc, MA, USA). Cervical cytology, colposcopy, biopsy and/or the loop electrosurgical excision procedure (LEEP) were performed in every examination. Results: The sensitivity of the HPV mRNA test in detecting high-grade squamous intraepithelial lesions (HSIL)/adenocarcinoma in situ (AIS)/cancer cases was as follows: for the vaginal self-samples 85.5% (95% CI; 75.0–92.8), the urinary samples 44.8% (95% CI; 32.6–57.4), and for routine cytology 81.7% (95% CI; 70.7–89.9). For the clinician-taken cervical HPV samples the sensitivity of the HPV mRNA test in detecting HSIL/AIS/cancer was 100.0% (95% CI; 94.9–100.0). The specificity of the HPV mRNA was similar for the clinician-taken cervical HPV samples and the self-samples: 49.0% vs. 48.1%. The urinary HPV samples had a specificity of 61.9% and cytology had a specificity of 93.3%. Conclusion: The sensitivity of the Aptima HPV mRNA test in detecting HSIL/AIS/cancer from vaginal self-samples was similar to that of routine cytology. The Aptima HPV mRNA vaginal self-sampling analysis may serve as a complement in screening programs.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
HPV analyses, HPV mRNA, Self-collected vaginal smear, Urinary sample
in
Journal of Clinical Virology
volume
101
pages
5 pages
publisher
Elsevier
external identifiers
  • scopus:85041539502
ISSN
1386-6532
DOI
10.1016/j.jcv.2018.02.002
language
English
LU publication?
yes
id
de043e59-d191-46d1-8996-7cda54528190
date added to LUP
2018-02-20 12:59:45
date last changed
2018-05-29 10:23:09
@article{de043e59-d191-46d1-8996-7cda54528190,
  abstract     = {<p>Background: In order to increase coverage in the organized cervical screening program, self-sampling with HPV analyses has been suggested. Objectives: The aim was to compare human papillomavirus (HPV) mRNA detection in vaginal and urine self-collected samples with clinician-taken cervical samples and the corresponding clinician-taken histological specimens. Study design: Self-collected vaginal, urine and clinician-taken cervical samples were analyzed from 209 women with the Aptima mRNA assay (Hologic Inc, MA, USA). Cervical cytology, colposcopy, biopsy and/or the loop electrosurgical excision procedure (LEEP) were performed in every examination. Results: The sensitivity of the HPV mRNA test in detecting high-grade squamous intraepithelial lesions (HSIL)/adenocarcinoma in situ (AIS)/cancer cases was as follows: for the vaginal self-samples 85.5% (95% CI; 75.0–92.8), the urinary samples 44.8% (95% CI; 32.6–57.4), and for routine cytology 81.7% (95% CI; 70.7–89.9). For the clinician-taken cervical HPV samples the sensitivity of the HPV mRNA test in detecting HSIL/AIS/cancer was 100.0% (95% CI; 94.9–100.0). The specificity of the HPV mRNA was similar for the clinician-taken cervical HPV samples and the self-samples: 49.0% vs. 48.1%. The urinary HPV samples had a specificity of 61.9% and cytology had a specificity of 93.3%. Conclusion: The sensitivity of the Aptima HPV mRNA test in detecting HSIL/AIS/cancer from vaginal self-samples was similar to that of routine cytology. The Aptima HPV mRNA vaginal self-sampling analysis may serve as a complement in screening programs.</p>},
  author       = {Asciutto, Katrin Christine and Ernstson, Avalon and Forslund, Ola and Borgfeldt, Christer},
  issn         = {1386-6532},
  keyword      = {HPV analyses,HPV mRNA,Self-collected vaginal smear,Urinary sample},
  language     = {eng},
  pages        = {69--73},
  publisher    = {Elsevier},
  series       = {Journal of Clinical Virology},
  title        = {Self-sampling with HPV mRNA analyses from vagina and urine compared with cervical samples},
  url          = {http://dx.doi.org/10.1016/j.jcv.2018.02.002},
  volume       = {101},
  year         = {2018},
}